This Specialized Program of Research Excellence (SPORE) in prostate cancer at the Mayo Clinic Comprehensive Cancer Center will support a multidisciplinary team of basic, clinical, and population science investigators to perform translational research directed at significantly reducing mortality from prostate carcinoma. Donald J. Tindall, Ph.D. will serve as the Principal Investigator. Michael M. Liebet, M.D. will serve as Co-Principal Investigator. The translational research objectives of the SPORE will be directed by six research projects: Project 1: Genetic Susceptibility in Prostate Cancer (Stephen N. Thibodeau, Ph.D., Michael L. Blute, M.D., Daniel J. Schaid, Ph.D., James R. Cerhan: M.D., Ph.D., Steven J. Jacobsen, M.D., Ph.D.) Project 2: Human Kallikreins as Novel Markers of Prostate Cancer (Charles Y.F. Young, George G. Klee, M.D., Ph.D. Donald J. Tindall, Ph.D., Michael Liebet, M.D.). Project 3: Biologic and Clinical Studies of the Over-represented 8q24 Region Associated with Prostate Cancer Progression (Robert B. Jenkins, M.D., Ph.D., Michael M. Liebet, M.D.). Project 4: An Immune-Based Therapeutic Approach for Prostate Cancer, (Esteban Celis, M.D., Ph.D., Patrick A. Burch, M.D.,). Project 5: Use of Fusogeoic Membrane Glycoproteins for Gene Therapy of Prostate Cancer (Richard G. Vile, Ph.D., Evanthia Galahis, M.D., Brian J. Davis, M.D., Torrance Wilson, M.D.). Project 6: Gene Therapy of Prostate Cancer using Radioactive Iodine (John C. Morris III, M.D., Brian J. Davis, M.D., Esteban Celis, M.D., Richard G. Vile, Ph.D.). Five core resources will support these research projects: Core 1: Administrative Core (Donald J. Tindall, Ph.D.). Core 2: Prostate Cancer Tissue Resource Core (John C. Cheville, M.D., Patrick Roche, Ph.D.). Core 3: Gene Discovery and Bioinformatics Core (George Vasmatzis, Ph.D., Stephen J. Itturria, Ph.D.). Core 4: Clinical Follow-up Core (Brian J. Davis, M.D., Mike Blute M.D., Patrick A. Burch, M.D., Thomas M. Pisansky, M.D.). Core 5: Biostatistics Core (Daniel J. Sargent, Ph.D., Susan Geyer, Ph.D., Erik J. Bergstrahl, M.S.). A Developmental Research Program has been established to explore opportunities for innovative research and a Career Development Program has been organized to facilitate young investigators to establish independence in prostate cancer translational research. The SPORE structure provides the ideal mechanism to focus and integrate the discovery efforts of investigators and to optimally utilize the clinical resources of the Mayo Clinic practice to make meaningful advances in the management of prostate cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Zhong, Jian; Ding, Liya; Bohrer, Laura R et al. (2014) p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res 74:1870-1880
Klee, Eric W; Bondar, Olga P; Goodmanson, Marcia K et al. (2014) Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences. Am J Clin Pathol 141:527-33

Showing the most recent 10 out of 206 publications